PAR — Paradigm Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- AU$100.18m
- AU$66.92m
- AU$8.49m
2019 June 30th | 2020 June 30th | 2021 June 30th | C2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.25 | 4.65 | 8.58 | 7.89 | 8.49 |
Cost of Revenue | |||||
Gross Profit | — | — | 8.48 | 7.75 | 8.47 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 18.9 | 16.9 | 43.2 | 48 | 60 |
Operating Profit | -15.6 | -12.3 | -34.6 | -40.1 | -51.5 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -15.6 | -12.3 | -34.3 | -39.2 | -51.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -15.6 | -12.3 | -34.3 | -39.2 | -51.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -15.6 | -12.3 | -34.3 | -39.2 | -51.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -15.6 | -12.3 | -34.3 | -39.2 | -51.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.059 | -0.059 | -0.162 | -0.163 | -0.18 |